AstraZeneca Canada Inc.

AstraZeneca Canada Inc.

AstraZeneca Canada Inc. is a wholly owned indirect subsidiary of
AstraZeneca PLC with global headquarters in London, England.
Shares of AstraZeneca PLC are traded publicly on the New York
Stock Exchange, London Stock Exchange and Stockholm Stock
Exchange under the symbol 'AZN'.

Established in April 1999, by a merger between Astra AB (Sweden)
and Zeneca PLC (U.K.).

Research and Development

AstraZeneca is one of the leading pharmaceutical companies, both
in Canada and worldwide, with a formidable product portfolio
spanning seven major therapeutic areas: cardiovascular,
gastrointestinal, oncology, pain control, respiratory, central
nervous system and infection. AstraZenecas brands include
Atacand, Losec, Zestril, Xylocaine, Arimidex, Pulmicort,
Zomig and Seroquel. The Canadian headquarters and
manufacturing facilities of AstraZeneca are located in
Mississauga, Ontario, with a state-of-the-art basic research
centre based in Montreal, Quebec.

AstraZeneca Canada Inc. is a research-driven company, which
believes that curiosity is the best way to express their
commitment to patient health. Looking beyond the obvious and
solving problems in innovative ways - this is what drives the
companys researchers forward in their hunt for new and better
treatments for a wide array of medical conditions and diseases.

AstraZeneca Canada Inc.s fundamental commitment to research and
development excellence is the foundation of the companys
formidable product portfolio. Their success ratio in bringing
new products to market is among the best in the pharmaceutical
industry. Moreover, their wide range of products makes
significant contributions to treatment options and patient care.

In Canada, AstraZeneca invests more than C$1.5 million every
week on research and the pursuit of new therapies. At
AstraZeneca R&D Montreal, more than 100 scientists are involved
in conducting leading-edge basic research dedicated to pain
treatment. Opened in 1997, the state-of-the-art research
facility has already filed patents on new discoveries that
AstraZeneca Canada Inc. hopes will improve the lives, not only
of Canadians, but also of people around the world. Montreal is a
cornerstone of the companys vision to become the global leader
in the overall therapeutic area of pain control.

AstraZeneca Canada Inc. prides itself on being a leader in
promoting research throughout Canada. The company is
particularly proud of the AstraZeneca Research Award program, a
multi-million dollar initiative operated in co-operation with
the Canadian Institutes of Health Research, Canadas Research-
Based Pharmaceutical Companies Research Program, and a number of
national health organizations. The Research Award program is
designed to fund research projects by up-and-coming scientists
at universities and medical institutions across the country.

AstraZeneca Canada Inc. is also proud to sponsor seven chairs at
four of Canadas leading universities. Such partnerships
provide outstanding training opportunities for talented young
researchers as well as world-renowned scientists. They also
enable AstraZeneca Canada Inc. to strengthen its ties between
industry and the leading-edge research of the Canadian academic
community.

AstraZeneca Canada Inc. also pursues strategic research
collaborations with external companies and academic institutions
to support and enhance their drug discovery and development
programs. As part of the medical affairs department at
AstraZeneca Canada Inc., the research liaison team actively
identifies and communicates information on novel Canadian
research and technology to AstraZenecas global R&D group. In
line with the overall drug discovery plan, areas of interest
include pre-clinical investigation involving molecular biology,
bioinformatics and combinatorial chemistry.

Company Details

Year Established: 1999

Total Sales ($CDN): $1,000,000 - $5,000,000

Number of Employees: 1500

Company Information

Alison Bing
Title: Corporate Affairs
Telephone: (905) 615-6828
Fax: (905) 270-3248
Email: Click Here

Sheila Frame
Title: Vice President, Corporate Affairs
Telephone: (905) 277-7111
Fax: (905) 275-7657

Felicia Shiu
Title: Director, Communications
Telephone: (905) 615-6865
Fax: (605) 275-7657
Email: Click Here

David Gannon
Title: Manager, Sheriden Park Environmental Lab
Telephone: (905) 403-2749
Fax: (905) 823-0047
Email: Click Here

Michelle Fleming
Title: Public Affairs
Telephone: (905) 615-6828
Fax: (905) 275-7657
Email: Click Here

Gerald Mcdole
Title: Chief Executive Officer
Area of Responsibility: Management Executive
Telephone: (905) 275-7111
Fax: (905) 277-2060

Products

Lidocaine, In Dosage, Human Use

Atropine, In Dosage, Human Use

Calcium Therapy Preps, In Dosage, Human Use

Epinephrine, In Dosage, Human Use

Salt /Sodium Chloride/ Nes

Water, Filtered, Sterilized, Purified

Potassium Chloride /Muriate Of Potash/

Dimenhydrinate, In Dosage, Human Use

Xenorem
XENOREM is a proprietary bioremediation technology for treating soils contaminated with chlorinated and non-chlorinated pesticides and other chlorinated organics. The process employs indigenous organisms and agricultural and other amendments for the treatment. Careful control of environmental conditions is critical for successful treatment.

Services

Biotechnology Zeneca is a leading international bioscience company which creates new products and services to improve human health and nutrition and the quality of life. Zeneca's Sheridan park Environmental Laboratory (SPEL)is part of Zeneca's Environmental Service Team, whose primary role is to meet the environmental needs of Zeneca's businesses in North America and around the world. SPEL's focus is the development and application of technologies for remediating site contaminants. SPEL has been particularly active in developing bioremediation technologies for soils contaminated with chlorinated organics and other refractory organics. An increasing effort is being devoted to the development of in-situ remediation technologies. Proprietary remediation technology is available for licensing and SPEL also offers laboratory and consulting services to external companies.

Bioremediation Services SPEL provides consulting services and laboratory studies in the areas of biotreatment and bioremediation. Areas covered include soil and groundwater and sediments as well as industrial effluents. Ex-situ and in-situ treatment approaches are included.